EN – Orixha https://orixha.com Liquid Ventilation for Life Thu, 12 Jun 2025 07:33:02 +0000 fr-FR hourly 1 https://wordpress.org/?v=6.9.4 https://orixha.com/wp-content/uploads/2023/10/Favicon.svg EN – Orixha https://orixha.com 32 32 June 2025 https://orixha.com/2025/06/12/june-2025/ Thu, 12 Jun 2025 07:14:18 +0000 https://orixha.com/?p=1582

France invests € 4M in Orixha’s reprocessing factory of breathable liquid for liquid ventilation

Lyon and Paris, May 20, 2025 – Orixha, a MedTech pioneer in liquid ventilation, announces that its (L2B)2 project for the industrial reprocessing of the L2B breathable liquid has been selected by the Première Usine program of France 2030 and will receive a grant plus loan award of 4 million euros. This financial support will enable Orixha to launch the scale-up and industrial phases of an exemplary reprocessing process in terms of technological and environmental innovation. Scheduled for commissioning in 2028 in the Plaine de l’Ain Industrial Park, this factory is essential to the commercialization of its Vent2Cool solution for resuscitated cardiac arrest patients.

Press Release
]]> March 2025 https://orixha.com/2025/03/24/march-2025/ Mon, 24 Mar 2025 13:20:39 +0000 https://orixha.com/?p=1502

Publication of theOverCool clinical trial protocol

Publication of the OverCool clinical trial protocol – Performance and Safety validation of Vent2Cool in Post Cardiac Arrest Syndrome

The OverCool study represents a world premiere for Total Liquid_Ventilation (TLV), and in the spirit of transparency, we wanted, together with the authors of the protocol, to publish it in the journal Resuscitation Plus.

You can access it for free by clicking on the following link:

Protocol
]]> September 2024 https://orixha.com/2024/09/05/september-2024/ Thu, 05 Sep 2024 09:47:43 +0000 https://orixha.com/?p=1427

ORIXHA obtains French Health Authority approval to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome

Paris, September the 5th, 2024 – Orixha announced that it received the approval from the ANSM (French National Agency for the Safety of Medicines and Health Products) and the Ethics Committee for the OverCool study to be conducted at Hopital Cochin (APHP Paris). The OverCool study aims to achieve two major clinical breakthroughs. First, it will validate the ability to induce therapeutic hypothermia within 2 hours post resuscitation, in order to significantly improve survival and neurological outcomes for cardiac arrest patients. Secondly, the OverCool study will achieve a clinical world premiere for total liquid ventilation as Vent2Cool’s ultra-rapid cooling performance is powered by Orixha’s proprietary lung conservative liquid ventilation technology platform.

Press Release
]]> May 2024 https://orixha.com/2024/05/30/may-2024/ Thu, 30 May 2024 13:11:42 +0000 https://orixha.com/?p=1127

Luncolive Project

The page dedicated to the Luncolive project is now online!

Consult it to find out about the progress of this R&D project on LUNCOLIVE technology funded by the EIC accelerator.

Luncolive Project
]]> Apr 2024 https://orixha.com/2024/04/11/apr-2024/ Thu, 11 Apr 2024 09:54:46 +0000 https://orixha.com/?p=1173

Orixha raises 4 million euros from the EIC Fund and Bpifrance

Lyon and Paris, April 10, 2024 – Orixha announces that it has raised 4 million euros from the European Innovation Council Fund and the French Tech Seed fund, managed on behalf of the French government France 2030 initiative by Bpifrance. This financing will enable Orixha to develop and validate in the clinic its total liquid ventilation technology, starting with resuscitated cardiac arrest patients in critical care.    

Press Release
]]> Oct 2022 https://orixha.com/2023/10/06/oct-2022/ Fri, 06 Oct 2023 14:22:54 +0000 http://www.test.orixha.com/?p=550

Orixha is laureate of the EIC Accelerator and receives 7,5 M€ for the LuncoLive project

With Luncolive, Orixha aims to promote the Liquid Ventilation as a new breakthrough technology in critical care.
Orixha announces that its Luncolive program has been selected by the European Innovation Council for a founding of 2.5 M€ and a capital investment of 5 M€, in order to improve the survival of post-cardiac arrest patients. This will allow to validate the clinical benefit of the Vent2Cool Solution in post-cardiac arrest syndrome and to explore and developp new medical applications in critical care.

Press release (Fr)
]]> Mar 2022 https://orixha.com/2023/10/06/march-2022/ Fri, 06 Oct 2023 14:15:10 +0000 http://www.test.orixha.com/?p=535

Orixha won the first prize for innovation at Medi'Nov Salon in Lyon

On march 31st, Orixha won the first prize of Innovation at Medi’Nov salon 2022. This competition was organized by the region Auvergne-Rhône-Alpes in France.

Press release (Fr)
]]> Nov 2021 https://orixha.com/2023/10/06/nov-2021/ Fri, 06 Oct 2023 13:59:01 +0000 http://www.test.orixha.com/?p=513

Orixha raises 2 millions euros for the development of the Vent2Cool solution

Orixha just annonced a foundraising of 2 million euros from Angels Santé, Erganeo and its industrial partners : Infiplast, OEM Development et Activation. This first round will allow to finalize the medical device Vent2Cool before starting the first clinical trial in cardiac arrest patients.

Press release (Fr)
]]> Sept 2021 https://orixha.com/2023/10/06/sept-2021/ Fri, 06 Oct 2023 13:47:22 +0000 http://www.test.orixha.com/?p=497

Orixha receives the financial support of "Programme d'Investissement d'Avenir" after being selected at the I-Nov

Press release (Fr)
]]>